Please login to the form below

Not currently logged in
Email:
Password:

PCSK9 inhibitor

This page shows the latest PCSK9 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Dupixent bounce-back helps stem diabetes declines at Sanofi

Dupixent bounce-back helps stem diabetes declines at Sanofi

Another Regeneron-partnered drug – and another key component for Sanofi’s specialty medicines drive – is cholesterol-lowering PCSK9 inhibitor Praluent (alirocumab), and while sales rose 55% year-on-year to 62m ... At the moment, Sanofi is losing

Latest news

  • Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use? Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

    This puts it ahead of its fellow PCSK9 product and rival, however Sanofi and Regeneron unveiled strong strong cardiovascular outcomes data from their ODYSSEY trial in combination with the huge cut ... However, the majority of patients in Europe who could

  • Esperion craters as deaths mar atherosclerosis drug study Esperion craters as deaths mar atherosclerosis drug study

    Esperion is hoping to position bempedoic as a once-daily, oral alternative to PCSK9 inhibitor such as Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab), which are given by ... Esperion recently reported phase II data showing

  • Segmentation, evolved Segmentation, evolved

    Along with results from its Odyssey Outcomes trial, Sanofi said that it plans to offer discounts of up to 69% to encourage payers to expand the use of the PCSK9 inhibitor. ... Research by Amgen, which has a PCSK9 called Repatha, suggests that two-thirds

  • Amgen gets prevention claim for cholesterol drug Repatha Amgen gets prevention claim for cholesterol drug Repatha

    The new label gives Amgen a promotional edge for Repatha (evolcoumab) over rival PCSK9 inhibitor Praluent (alirocumab) from Sanofi and Regeneron as it tries to rev up sales of its product, ... their ability to sell the PCSK9 inhibitor in the US market.

  • US court lifts ban on sales of Sanofi's Praluent US court lifts ban on sales of Sanofi's Praluent

    A US appeals court has overturned a lower court judgment that Sanofi and Regeneron should be barred from selling their PCSK9 inhibitor Praluent in the US because of patent infringement. ... PCSK9 inhibitor developer Amgen.

More from news
Approximately 10 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... In July, BioMarin sold its PRV to Regeneron for $68m to expedite filing of its cholesterol drug, the PCSK9

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics